Diffuse involvement of the pancreas in neuroendocrine tumor is a rare presentation, and its appearance on In-111 pentetreotide scan has not been reported earlier in the literature. We present the whole body images from In-111 pentetreotide scan, contrast-enhanced computed tomography images, and histopathology correlation.
A 31-year-old female presented to the emergency department with abdominal pain, nausea, and vomiting. Computed tomography (CT) scan of the abdomen showed diffuse enlargement of the pancreas with a hypervascular focus in the tail of the pancreas, suspicious for a neuroendocrine tumor. An In-111 pentetreotide scan was performed, which showed diffuse increased uptake in an enlarged pancreas [ Figure 1a and b]. The normal distribution is seen in the spleen, liver, kidneys, and the urinary bladder. No focal lesions or metastatic disease was seen. Corresponding transaxial image [ Figure 1c ] from the contrast-enhanced CT scan of the abdomen and pelvis shows diffusely enlarged pancreatic body and tail (dashed white arrows) and a focal hypervascular lesion in the tail of the pancreas. A distal pancreatectomy was performed, which showed diffuse involvement of the pancreas with a neuroendocrine tumor [ Figure 1d ]. A completion total pancreatectomy (Whipple's procedure) was later performed which showed a low-grade diffuse pancreatic neuroendocrine tumor. There was a local invasion of the duodenum with negative margins and no evidence of nodal metastasis. The neuroendocrine differentiation was confirmed on immunohistochemical staining with markers such as chromogranin A [ Figure 1e ] and Synaptophysin (not shown). Ki67 index (a marker of cellular proliferation) was <2%, suggesting a low-grade tumor.
Pancreatic neuroendocrine tumors are rare tumors that are typically classified as functional versus nonfunctional (based on laboratory testing) and differentiated versus de-differentiated (based on the immunohistochemistry). [1] [2] [3] They usually present as a focal hypervascular mass on CT imaging, hyperdense on the arterial, and portal venous phases. [4] [5] [6] Since these tumors are neuroendocrine in origin, they express somatostatin receptors on their cell membranes, a binding site for In-111 pentetreotide. In-111 pentetreotide imaging is performed for confirmation (of neuroendocrine origin), whole body staging, and assessing response to treatment. [7] [8] [9] Pancreatic neuroendocrine tumors and metastasis are seen as foci of increased uptake on whole-body imaging with In-111 pentetreotide. [9] Single-photon emission computed tomography (CT) imaging has been reported to be useful for anatomical localization of metastatic disease when using In-111 pentetreotide. [10] Diffuse pancreatic infiltration with neuroendocrine tumor is a rare presentation, previously reported once on anatomic imaging. [6, 11] Diffuse uptake of In-111 pentetreotide has previously been reported in the lungs, [12, 13] but diffuse uptake in the pancreas from a neuroendocrine tumor has not been reported previously. In conclusion, this case highlights a rare presentation of a well-differentiated, low-grade neuroendocrine tumor as the diffuse involvement of the pancreas, with local invasion, but no nodal or distant metastasis.
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